patent.fyi
Applications  /  US 2026/0355227
United States Patent Application Publication

US 2026/0355227 A1

Published
Nov 12, 2026
Filed
Sep 17, 2025
Earliest date on the face
Apr 29, 2025
Classification
A61K 31/7048
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Muscle contraction increases glucose uptake

What ifWhat if repeated skeletal muscle contraction increases glucose uptake?
Claim language“a CS-GAG inhibitor”

During cycling, contracting muscle fibers activate calcium-dependent and energy-sensing pathways that move glucose transporter 4 to the cell surface. Repeated exercise sessions increase skeletal muscle responsiveness to insulin.

1.1Biguanide reduces hepatic glucose output

What ifWhat if an oral biguanide reduces excessive hepatic glucose output?
Claim language“a CS-GAG inhibitor”

An oral biguanide enters hepatocytes through organic cation transporters and reduces hepatic gluconeogenesis. Lower hepatic glucose release reduces fasting plasma glucose in type 2 diabetes.

1.1Receptor activation improves insulin sensitivity

What ifWhat if a thiazolidinedione improves insulin sensitivity through a nuclear receptor in adipose tissue?
Claim language“a CS-GAG inhibitor”

The thiazolidinedione activates peroxisome proliferator-activated receptor gamma and changes transcription of genes involved in adipocyte differentiation and lipid handling. Greater lipid storage in adipose tissue reduces circulating free fatty acids and improves insulin responsiveness in skeletal muscle.

1.1Renal glucose reabsorption decreases

What ifWhat if a renal glucose transporter inhibitor lowers plasma glucose by increasing urinary glucose excretion?
Claim language“a CS-GAG inhibitor”

A small molecule inhibits sodium-glucose cotransporter 2 in the renal proximal tubule. Less filtered glucose returns to the bloodstream, which lowers plasma glucose in type 2 diabetes.

1.2Reduced 4-epimerase activity lowers precursor supply

What ifWhat if a 4-epimerase inhibitor reduces the supply of a sugar precursor for chondroitin sulfate synthesis?
Claim language“not a 4-epimerase inhibitor”

In cultured cells, a small interfering RNA reduces expression of UDP-galactose 4-epimerase, which interconverts UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine. Targeted mass spectrometry measures the intracellular UDP-N-acetylgalactosamine pool and the chondroitin sulfate disaccharides recovered after digestion.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Insulin response screening in cultured adipocytes

A cell screening laboratory cultures differentiated adipocytes in a multiwell plate and applies a chondroitin sulfate glycosaminoglycan inhibitor to the culture medium. Matched wells receive vehicle, and each treatment has wells with and without an insulin challenge. The assay measures cell-associated labeled glucose analog and normalizes uptake to cell count to quantify the insulin response.

Component substitution

Extracellular chain cleavage with chondroitinase ABC

Chondroitinase ABC replaces a biosynthesis inhibitor in an ex vivo adipose tissue assay. The enzyme is added to the medium surrounding tissue explants, where it cleaves extracellular chondroitin sulfate chains. The explants are washed before an insulin challenge, and the assay measures labeled glucose uptake alongside released chondroitin sulfate fragments.

Parameter or scale variation

Two exposure windows in adipose explants

Matched adipose explants receive the same concentration of a chondroitin sulfate glycosaminoglycan inhibitor for either 6 or 24 hours. The 6-hour exposure starts 18 hours after the 24-hour exposure so both groups finish at the same time. Both groups then receive a 30-minute insulin challenge, and the assay measures labeled glucose uptake per milligram of tissue protein against time-matched vehicle controls.

Combination with existing systems

Inhibitor administration with glucose clamp monitoring

A preclinical study pairs inhibitor administration with a hyperinsulinemic euglycemic clamp in catheterized animals. Separate infusion lines deliver insulin at a fixed rate and glucose at a variable rate, while serial blood glucose measurements guide glucose infusion adjustments. The mean glucose infusion rate during the steady-state interval serves as the insulin sensitivity readout for inhibitor and vehicle groups.

Inhibitor delivery through an osmotic pump

A preclinical study delivers a soluble chondroitin sulfate glycosaminoglycan inhibitor through an implantable osmotic pump with a subcutaneous outlet. The pump delivers the formulation at a fixed volumetric rate, and the formulation concentration determines the delivered mass per unit time. Animals with vehicle-filled pumps serve as controls, and timed plasma sampling and insulin tolerance measurements track exposure and response.

Automated or data-driven variant

Automated measurement of insulin response curves

A liquid handler dispenses a dilution series of a chondroitin sulfate glycosaminoglycan inhibitor into adipocyte wells and delivers timed insulin and fluorescent glucose analog additions. A plate reader records fluorescence after washing, and analysis software subtracts background and normalizes each well to its cell count. The software fits concentration-response curves to the insulin-stimulated uptake signal and flags concentrations that reduce viability in matched wells.

Specific version of a part

Oral fluorinated sugar derivative

Administer a fluorinated N-acetylglucosamine derivative by oral gavage in a preclinical study. Measure tissue chondroitin sulfate after enzymatic digestion and use the reduction in recovered disaccharides as a measure of target engagement.

Chondroitin synthase expression knockdown

Deliver a small interfering RNA against chondroitin synthase 1 to cultured cells in lipid particles. Reduced synthase expression limits elongation of chondroitin chains by reducing the enzyme available to add glucuronic acid and N-acetylgalactosamine residues.

Xylosyltransferase expression knockdown

Use a small interfering RNA against xylosyltransferase 1 in cells that express it. The knockdown reduces transfer of xylose to serine residues on proteoglycan core proteins, limiting formation of the linkage sites used to initiate chondroitin sulfate chains.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0318465 A1
Published
Dec 24, 2009
Filed
Sep 20, 2007
Class
A61K 31/496
Document BUS 2023/0051911 A1
Published
Feb 16, 2023
Filed
Aug 2, 2021
Class
A61K 31/192
Claim 1
Document A
Document B
1.1administering an effective amount of a CS-GAG inhibitor, or pharmaceutically acceptable salt, solvate or hydrate thereof, to the subject
A method for the treatment of disorders caused by insulin resistance to glucose uptake and disorders related thereto comprising administering to a mammal in need thereof a therapeutically effective amount of a compound, wherein said compound is identified as a lead compound by a method of identifying a lead compound which act as an insulin-sensitizer, wherein said method comprising: subjecting test compounds to screening using an adipogenesis assay; determining whether the te
A · US 2009/0318465 A1 · claim 8
Methods of treating or ameliorating multiple sclerosis by the dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus or a pharmaceutically acceptable salt and/or a solvate, in particular a hydrate, thereof or a solvate, in particular a hydrate, of a pharmaceutically acceptable salt thereof, by administering to a human patient a therapeutically effective amount of the DHODH inhibitor, more specifically a daily dose of about 10 mg to about 45 mg.
B · US 2023/0051911 A1 · abstract
1.2wherein the CS-GAG inhibitor is not a 4-epimerase inhibitor.

An empty cell means only that no passage was reproduced there.

Statements in these documents
This method can identify lead compounds for the treatment of diseases caused by insulin resistance.
A · US 2009/0318465 A1 · ¶ 2
This invention also includes methods for treating insulin resistance and related disorders such as diabetes, obesity and dyslipidemia.
A · US 2009/0318465 A1 · ¶ 2
Use of teriflunomide can be limited by its side effect profile: diarrhoea, alopecia, neutropenia, and elevated liver enzymes.
B · US 2023/0051911 A1 · ¶ 5
Vidofludimus calcium has a half-life of approximately 30 h that allows for once-daily oral dosing and rapid wash-out at treatment discontinuation (Eur.
B · US 2023/0051911 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355227 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355227/, SHA-256 cf119a4c6d6a37c67fed97747dacfd81a1a579f2a20f6eb2c2360da12dfdcdd0
First published
Permanent addresshttps://patent.fyi/US20260355227/
Content fingerprint (SHA-256)cf119a4c6d6a37c67fed97747dacfd81a1a579f2a20f6eb2c2360da12dfdcdd0
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi